AbbVie and R-Pharm win large state contract in Russia

5 July 2018

R-Pharm, one of Russia’s leading drugmakers, together with the USA’s AbbVie (NYSE: ABBV) have won a tender for the supply of one of the most sought after anti-HIV drugs – Kaletra (lopinavir plus ritonavir) for the needs of the state, according to the company and the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.

The total amount of the contract, which is for the period to November 15 of the current year is estimated at about 5 billion roubles ($80 million), which makes it one of the largest contracts in the Russian industry of drug public procurements, signed this year.

Farmasintez, which last year registered the first generic of Kaletra - Kalidavir, did not participate in the tender due to its strict requirements (mainly short delivery time ), despite the fact that a price for its generic was about 20% lower than for Kaletra.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK